790 related articles for article (PubMed ID: 29133079)
1. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats.
Shi R; Wei Z; Zhu D; Fu N; Wang C; Yin S; Liang Y; Xing J; Wang X; Wang Y
Pulm Pharmacol Ther; 2018 Feb; 48():124-135. PubMed ID: 29133079
[TBL] [Abstract][Full Text] [Related]
2. Thymoquinone attenuates monocrotaline-induced pulmonary artery hypertension via inhibiting pulmonary arterial remodeling in rats.
Zhu N; Zhao X; Xiang Y; Ye S; Huang J; Hu W; Lv L; Zeng C
Int J Cardiol; 2016 Oct; 221():587-96. PubMed ID: 27420584
[TBL] [Abstract][Full Text] [Related]
3. Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition.
Shi R; Zhu D; Wei Z; Fu N; Wang C; Liu L; Zhang H; Liang Y; Xing J; Wang X; Wang Y
Life Sci; 2018 Aug; 207():442-450. PubMed ID: 29969608
[TBL] [Abstract][Full Text] [Related]
4. Betaine Attenuates Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats via Inhibiting Inflammatory Response.
Yang JM; Zhou R; Zhang M; Tan HR; Yu JQ
Molecules; 2018 May; 23(6):. PubMed ID: 29861433
[TBL] [Abstract][Full Text] [Related]
5. A urotensin II receptor antagonist, KR36676, decreases vascular remodeling and inflammation in experimental pulmonary hypertension.
Lee JH; Park BK; Oh KS; Yi KY; Lim CJ; Seo HW; Lee BH
Int Immunopharmacol; 2016 Nov; 40():196-202. PubMed ID: 27611861
[TBL] [Abstract][Full Text] [Related]
6. Formononetin attenuates monocrotaline‑induced pulmonary arterial hypertension via inhibiting pulmonary vascular remodeling in rats.
Cai C; Xiang Y; Wu Y; Zhu N; Zhao H; Xu J; Lin W; Zeng C
Mol Med Rep; 2019 Dec; 20(6):4984-4992. PubMed ID: 31702810
[TBL] [Abstract][Full Text] [Related]
7. Perillyl alcohol suppresses monocrotaline-induced pulmonary arterial hypertension in rats via anti-remodeling, anti-oxidant, and anti-inflammatory effects.
Beik A; Najafipour H; Joukar S; Rajabi S; Iranpour M; Kordestani Z
Clin Exp Hypertens; 2021 Apr; 43(3):270-280. PubMed ID: 33322932
[No Abstract] [Full Text] [Related]
8. Tetrandrine prevents monocrotaline-induced pulmonary arterial hypertension in rats through regulation of the protein expression of inducible nitric oxide synthase and cyclic guanosine monophosphate-dependent protein kinase type 1.
Wang X; Yang Y; Yang D; Tong G; Lv S; Lin X; Chen C; Dong W
J Vasc Surg; 2016 Nov; 64(5):1468-1477. PubMed ID: 26527422
[TBL] [Abstract][Full Text] [Related]
9. Activation of AMPK prevents monocrotaline-induced pulmonary arterial hypertension by suppression of NF-κB-mediated autophagy activation.
Zhai C; Shi W; Feng W; Zhu Y; Wang J; Li S; Yan X; Wang Q; Zhang Q; Chai L; Li C; Liu P; Li M
Life Sci; 2018 Sep; 208():87-95. PubMed ID: 30009823
[TBL] [Abstract][Full Text] [Related]
10. Resveratrol inhibits monocrotaline-induced pulmonary arterial remodeling by suppression of SphK1-mediated NF-κB activation.
Shi W; Zhai C; Feng W; Wang J; Zhu Y; Li S; Wang Q; Zhang Q; Yan X; Chai L; Liu P; Chen Y; Li M
Life Sci; 2018 Oct; 210():140-149. PubMed ID: 30179628
[TBL] [Abstract][Full Text] [Related]
11. Forsythoside B Mitigates Monocrotaline-Induced Pulmonary Arterial Hypertension via Blocking the NF-κB Signaling Pathway to Attenuate Vascular Remodeling.
Liu J; Fang G; Lan C; Qiu C; Yao L; Zhang Q; Hu J; Zhang Y; Yang Y; Zhang Y
Drug Des Devel Ther; 2024; 18():767-780. PubMed ID: 38495631
[TBL] [Abstract][Full Text] [Related]
12. Aspirin attenuates monocrotaline-induced pulmonary arterial hypertension in rats by suppressing the ERK/MAPK pathway.
Gao H; Cheng Y; Zong L; Huang L; Qiao C; Li W; Gong B; Hu J; Liu H; Wang X; Zhao C
Clin Exp Hypertens; 2017; 39(1):34-41. PubMed ID: 28055284
[TBL] [Abstract][Full Text] [Related]
13. Srolo Bzhtang reduces inflammation and vascular remodeling via suppression of the MAPK/NF-κB signaling pathway in rats with pulmonary arterial hypertension.
Chen T; Su S; Yang Z; Zhang D; Li Z; Lu D
J Ethnopharmacol; 2022 Oct; 297():115572. PubMed ID: 35872290
[TBL] [Abstract][Full Text] [Related]
14. Ellagic acid prevents monocrotaline-induced pulmonary artery hypertension via inhibiting NLRP3 inflammasome activation in rats.
Tang B; Chen GX; Liang MY; Yao JP; Wu ZK
Int J Cardiol; 2015 Feb; 180():134-41. PubMed ID: 25438234
[TBL] [Abstract][Full Text] [Related]
15. Hydroxysafflor yellow A improves established monocrotaline-induced pulmonary arterial hypertension in rats.
Han X; Zhang Y; Zhou Z; Zhang X; Long Y
J Int Med Res; 2016 Jun; 44(3):569-84. PubMed ID: 27059291
[TBL] [Abstract][Full Text] [Related]
16. Astragalus Polysaccharides Attenuate Monocrotaline-Induced Pulmonary Arterial Hypertension in Rats.
Yuan LB; Hua CY; Gao S; Yin YL; Dai M; Meng HY; Li PP; Yang ZX; Hu QH
Am J Chin Med; 2017; 45(4):773-789. PubMed ID: 28521513
[TBL] [Abstract][Full Text] [Related]
17. Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Leong ZP; Hikasa Y
Vascul Pharmacol; 2018 Nov; 110():31-41. PubMed ID: 30071297
[TBL] [Abstract][Full Text] [Related]
18. Salvianolic acid A attenuates vascular remodeling in a pulmonary arterial hypertension rat model.
Chen YC; Yuan TY; Zhang HF; Wang DS; Yan Y; Niu ZR; Lin YH; Fang LH; Du GH
Acta Pharmacol Sin; 2016 Jun; 37(6):772-82. PubMed ID: 27180980
[TBL] [Abstract][Full Text] [Related]
19. Glycyrrhizin, inhibitor of high mobility group box-1, attenuates monocrotaline-induced pulmonary hypertension and vascular remodeling in rats.
Yang PS; Kim DH; Lee YJ; Lee SE; Kang WJ; Chang HJ; Shin JS
Respir Res; 2014 Nov; 15():148. PubMed ID: 25420924
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of nuclear factor-κB in the lungs prevents monocrotaline-induced pulmonary hypertension in mice.
Li L; Wei C; Kim IK; Janssen-Heininger Y; Gupta S
Hypertension; 2014 Jun; 63(6):1260-9. PubMed ID: 24614212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]